HLAL RDNA Construct in SBC LAL-C Chickens: Package Insert and Label Information

HLAL RDNA CONSTRUCT IN SBC LAL-C CHICKENS- hlal rdna construct in sbc lal-c chicken not applicable
Alexion Pharmaceuticals, Inc.

Heritable construct

1. PRODUCT IDENTIFICATION

hLAL rDNA construct integrated at a single site (the SYN LAL-C site in chromosome 6) as a single copy, in a specific, diploid line (SBC LAL-C 1) of hemizygous and homozygous domestic chickens (Gallus gallus) derived from the lineage progenitor XLL 109, expressing a recombinant human lysosomal acid lipase (rhLAL) encoding gene such that rhLAL protein (intended for the treatment of humans) is present in their egg whites.


1
SBC LAL-C is the name Alexion designated for their lineage of chickens, and is not representative of the regulated article, which is subject to FDA approval. The FDA-regulated article subject to this approval is the intentional genomic alteration (hLAL rDNA construct) in the chickens.

2. WARNINGS AND PRECAUTIONS

SBC LAL-C chickens, or any materials derived from them, are not intended to enter the human or animal food supply.

3. ANIMAL SAFETY

Data from the following comparisons of SBC LAL-C chickens to comparator chickens (without an intentional genomic alteration; IGA) demonstrated a lack of adverse effect due to the rDNA construct, or to the recombinant human LAL protein, on the SBC LAL-C chicken.

Mortality rates 2 for SBC LAL-C chickens and comparators without an IGA housed under similar conditions are presented in Table 1. These data include mortality rates collected at multiple Alexion animal facilities housing multiple generations of SBC LAL-C chickens collected during 2015 to 2017.

Table 1: Historical Mortality Results for SBC LAL-C Hens (Measured by Age)
Hen Age (weeks) 21-25 26-30 31-35 36-40 41-45 46-50 51-55 56-60 61-65 66-70 71-75 76-80
*
Based on data from 19 populations, years 2015 through 2017
Comparator chickens (hens) are those without an intentional genomic alteration
Average Weekly Mortality Rate * 0.05% 0.10% 0.22% 0.17% 0.21% 0.19% 0.26% 0.39% 0.38% 0.37% 0.38% 0.74%
Standard Deviation 0.12% 0.19% 0.30% 0.28% 0.32% 0.32% 0.32% 0.42% 0.46% 0.44% 0.47% 1.34%
Comparator Hens 0% 0.13% 0.20% 0.48% 0.07% 0.07% 0.58% 0.23% 0.17% N/A N/A N/A

In a study to compare physiological endpoints SBC LAL-C vs. comparator chickens without an IGA, blood samples were collected for serological assays, and chickens were presented for post-mortem examination for gross/histological evaluations. No differences between LAL-C chickens and comparators without an IGA were evident based on the following evaluations: serology and histopathology, including CBC (complete blood count), comprehensive blood chemistry, triglycerides and LDH (lactate dehydrogenase) and histopathological examination of multiple tissues.

SBC LAL-C hens produced eggs over a 3-year period at the same average annual rate as comparator hens without an IGA housed under similar conditions (Table 2).

These values are also consistent with the 280 eggs per hen produced per year reported for White Leghorn flocks in commercial egg production facilities 3.

Table 2:Egg Production Rates for LAL-C Chickens and Comparators without an Intentional Genomic Alteration
Hen Age (weeks) 25 30 35 40 45 50 55 60 65 70
*
Based on data from eight production rooms at two production facilities
Comparator chickens (hens) are those without an intentional genomic alteration
SBC LAL-C Hens:
Average * 28.9 58.4 87.4 116.2 145.9 174.4 201.6 224.2 247.5 272.1
Standard Deviation 4.3 4.3 5.3 6.3 7.7 8.7 9.8 11.3 13.7 14.7
Comparator Hens
Average 31 63 93 118 147 173 198 222 248 274

The data for SBC LAL-C chickens versus comparator chickens without an IGA demonstrates no significant differences in, mortality, general health status or egg production.


2
Mortality as attributed to animal death and euthanasia for items such as broken legs/wings, cloacal prolapse or other injury.
3
Austic, R. E., Nesheim, M. C. Poultry production, 1990, Lea & Febiger, Philadelphia, US

4. EFFECTIVENESS

Multiple generations of the SBC LAL-C line have demonstrated genetic consistency as established through genetic tests for the presence of the hLAL rDNA construct, hLAL rDNA DNA sequence fidelity and hLAL rDNA construct integration site consistency. For each generation, phenotypic consistency has been established based on the presence of recombinant human LAL enzyme activity in egg white.

5. LIMITATIONS OF USE

The SBC LAL-C lineage must be housed in only those Alexion Pharmaceutical, Inc. facilities specified in the approved application.

Manufactured by:

Alexion Pharmaceuticals, Inc.

121 Seaport Boulevard,

Boston, MA 02210.

Approved by FDA under NADA #141-453

[version 002/2020]

November/2020
Alexion Pharmaceuticals, Inc.

hLAL rDNA Construct in SBC LAL-C Chickens

hLAL rDNA Construct in SBC LAL-C Chickens
(click image for full-size original)
HLAL RDNA CONSTRUCT IN SBC LAL-C CHICKENS
hlal rdna construct in sbc lal-c chicken not applicable
Product Information
Product Type Item Code (Source) NDC:25682-020
Route of Administration NOT APPLICABLE DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
HLAL RDNA CONSTRUCT IN SBC LAL-C CHICKEN (HLAL RDNA CONSTRUCT IN SBC LAL-C CHICKEN) HLAL RDNA CONSTRUCT IN SBC LAL-C CHICKEN 1 [arb’U] in 1 [arb’U]
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:25682-020-01 1 [arb’U] in 1 NOT APPLICABLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NADA NADA141453 12/08/2015
Labeler — Alexion Pharmaceuticals, Inc. (789359510)

Revised: 06/2021 Alexion Pharmaceuticals, Inc.

DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2021. All Rights Reserved.